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HIV-1 Tat Protein Modulates the Generation of Cytotoxic T
Cell Epitopes by Modifying Proteasome Composition and
Enzymatic Activity1
Riccardo Gavioli,2* Eleonora Gallerani,* Cinzia Fortini,* Marina Fabris,† Arianna Bottoni,*
Alessandro Canella,* Angela Bonaccorsi,† Mauro Marastoni,‡ Fabiola Micheletti,§
Aurelio Cafaro,§ Paola Rimessi,† Antonella Caputo,† and Barbara Ensoli§
Tat, the trans activation protein of HIV, is produced early upon infection to promote and expand HIV replication and transmis-
sion. However, Tat appears to also have effects on target cells, which may affect Ag recognition both during infection and after
vaccination. In particular, Tat targets dendritic cells and induces their maturation and Ag-presenting functions, increasing Th1
T cell responses. We show in this work that Tat modifies the catalytic subunit composition of immunoproteasomes in B and T cells
either expressing Tat or treated with exogenous biological active Tat protein. In particular, Tat up-regulates latent membrane
protein 7 and multicatalytic endopeptidase complex like-1 subunits and down-modulates the latent membrane protein 2 subunit.
These changes correlate with the increase of all three major proteolytic activities of the proteasome and result in a more efficient
generation and presentation of subdominant MHC-I-binding CTL epitopes of heterologous Ags. Thus, Tat modifies the Ag
processing and modulates the generation of CTL epitopes. This may have an impact on both the control of virally infected cells
during HIV-1 infection and the use of Tat for vaccination strategies. The Journal of Immunology, 2004, 173: 3838–3843.
T at is a regulatory protein of HIV-1 produced very earlyafter infection and essential for HIV-1 gene expression,replication, and infectivity (1). During acute infection of
T cells by HIV-1, Tat is also released in the extracellular milieu in
the absence of cell death or permeability changes (2–4). Extracel-
lular Tat is taken up by neighbor cells, where it modulates viral
and/or cellular functions depending on the protein concentration,
conformational state, and cell type (2–6). In addition, native Tat
protein targets and is very efficiently taken up by monocyte-de-
rived dendritic cells (DC),3 and, after internalization, it induces DC
maturation, augmenting allogeneic and Ag-specific presentation by
DC and increasing Th1 responses against recall Ags (6). We have
shown recently that vaccination with the Tat protein or tat DNA
protects monkeys against challenge with pathogenic simian HIV,
and that this protection correlates with Th1 responses and CTL
activity (7, 8).
CTLs recognize peptide epitopes expressed at the surface of target
cells in association with MHC class I molecules. The major enzymatic
activity responsible for the generation of class I-associated peptides is
that of the proteasome, a large multicatalytic protease that is essential
for the degradation of intracellular proteins (9). Proteasomes have
three distinct catalytic  subunits called 1, 2, and 5, which exhibit
postacidic, tryptic-like, and chymotryptic-like activity, respectively
(10). When cells are exposed to IFN-, these three catalytic subunits
are substituted with new components termed latent membrane protein
2 (LMP2), LMP7, and multicatalytic endopeptidase complex like-1
(MECL1), which are incorporated into a modified proteasome form
known as immunoproteasome (11). The proteolytic activity of immu-
noproteasomes is characterized by a reduced cleavage after acidic
amino acids and by an increased cleavage after hydrophobic and basic
residues, which are the most frequent residues found at the COOH
terminus of MHC class I-binding peptides (12, 13).
It has recently been shown that the Tat protein interacts with
both  subunits and LMP7 and MECL1 catalytic subunits of the
proteasome (14), and that Tat inhibits the proteolytic activity of
20S proteasome by competing with PA28 regulator for binding to
20S (15, 16). In this study, we analyzed the subunit composition
and activity of immunoproteasomes expressed in cells endog-
enously expressing Tat or treated with a fully active exogenous Tat
protein. We showed that Tat affects the subunit composition of
immunoproteasomes and increases all three major proteolytic ac-
tivities. This results in more efficient generation and presentation
of subdominant MHC-I-binding CTL epitopes derived from
heterologous Ags.
Materials and Methods
Cells
Lymphoblastoid cell lines (LCL) were established by in vitro infection of
B lymphocytes from healthy donors (MIN and MON) with the B95.8 strain
of EBV. Transduction of HIV tat (BH10 clone) into MIN and MON LCLs
was performed by infection with the retroviral vector pBabeP carrying the
puromycin resistance gene (17). Puromycin-selected cells were tested for
the presence and expression of tat by DNA-PCR, RT-PCR, and Northern
blot analysis. Jurkat T cells expressing Tat have been previously described
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(18). Cells were cultured in medium supplemented with 800 g/ml neo-
mycin (Sigma-Aldrich, St. Louis, MO). Control cells and cells expressing
Tat presented similar amounts of HLA class I molecules and adhesion
molecules as judged by immunofluorescence analysis using mAbs specific
for HLA-A,-B,-C, HLA-A2, HLA-DR, CD40, CD11a, CD80, and CD86
molecules (BD Pharmingen, San Diego, CA).
HIV-1 Tat protein
HIV-1 Tat from the human T lymphotropic virus type IIIB isolate (BH10
clone) was expressed in Escherichia coli and purified by heparin-affinity
chromatography and HPLC, as described previously (6). The lyophilized
Tat protein was stored at 80°C to prevent oxidation, reconstituted in
degassed buffer before use, and handled, as described (3). Different lots of
Tat were used with reproducible results, and, in all cases, endotoxin con-
centration was undetectable (detection threshold: 0.05 EU/g).
Purification of proteasomes
Cells were lysed with glass beads, as previously described (19). Superna-
tants were ultracentrifuged for 1 h at 100,000  g and loaded into an
affinity column containing a matrix derivatized with the MCP21 mAb spe-
cific for the 2 subunit of the proteasome (Affinity Technology, Exeter,
U.K.). Proteasomes were eluted with 25 mM Tris-HCl, pH 7.5, containing
2 M NaCl, and 0.5-ml fractions were collected. Homogeneity of the eluted
material was confirmed by analysis of an aliquot by 12% SDS-PAGE and
Coomassie blue staining of the gel. Fractions containing proteasomes were
combined and dialyzed against 25 mM Tris-HCl, pH 7.5. Protein concen-
tration was determined using the bicinchoninic acid method (Pierce,
Rockford, IL).
Western blot assay
Equal amounts of proteins or equal amounts of purified proteasomes were
loaded on a 12% SDS-PAGE and electroblotted onto Protran nitrocellulose
membranes (Schleicher & Schuell Microscience, Keene, NH). Blots were
probed with Abs specific for 2, LMP2, LMP7, MECL1, and PA28 sub-
units (Affinity) and developed by ECL (Amersham Biosciences, Uppsala,
Sweden).
Enzymatic assays
The chymotrypsin-like, trypsin-like, and postacidic activities of purified
proteasomes were tested using the fluorogenic substrates Suc-LLVY-
AMC, Boc-LRR-AMC, and Ac-YVAD-AMC, respectively, as previously
described (19). Fluorescence was determined by a fluorometer (Spec-
trafluor plus; Tecan, Salzburg, Austria). Proteasome activity is expressed as
arbitrary fluorescence units. The in vitro degradation of CLGGLLTMVA-
GAVW (CLG  5) was performed using 500 g of peptide and 127 g of
purified proteasomes in 300 l of activity buffer at 37°C. At different time
points, 60 l of sample was collected, and the reaction was stopped by
adding 2 vol of ethanol at 0°C. Digestion mixtures were centrifuged, and
80 l of supernatants was collected and separated by HPLC. Fractionation
was simultaneously monitored at 210 and 280 nm. Fractions were collected
and tested by IFN- ELISPOT assays.
Synthetic peptides
Peptides were synthesized by solid phase method and purified by HPLC to
98% purity, as previously described (20). Structure verification was per-
formed by elemental and amino acid analysis and mass spectrometry. Pep-
tides were dissolved in DMSO at 102 M, kept at 20°C, and diluted in
PBS before use.
Generation of CTL cultures
HLA A11-restricted EBV-specific CTL cultures reacting against the EBV-
encoded nuclear Ag 4 (EBNA4)-derived IVTDFSVIK (IVT, aa 416–424)
and AVFSRKSDAK (AVF, aa 399–408) epitopes (21) were obtained by
stimulation of lymphocytes from the HLA-A11-positive EBV-seropositive
donor MC with the autologous LCL. HLA-A2-restricted EBV-specific
CTL cultures reacting against the LMP2-derived CLGGLLTMV (CLG, aa
426–434) epitope (22) and the LMP1-derived YLQQNWWTL (YLQ, aa
159–167) epitope (23) were obtained by stimulation of lymphocytes from
the HLA-A2-positive EBV-seropositive donor RG with peptide-pulsed T2
cells, as previously described (24). CTL cultures were maintained in me-
dium supplemented with 10 U/ml rIL-2 (Chiron, Milan, Italy).
Cytotoxicity assay
Target cells were labeled with Na251CrO4 for 90 min at 37°C. Cyto-
toxicity tests were routinely run at different E:T ratios in triplicate.
Percentage of specific lysis was calculated as 100  (cpm sample 
cpm medium)/(cpm Triton X-100  cpm medium) (21). Spontaneous
release was always 20%.
ELISPOT assay
CTLs (4  104) were seeded in triplicate on microplate 96-well unifilter
(Whatman, Maidstone, Kent, U.K.) coated with an anti IFN- mAb
(Pierce). CTLs were stimulated with 20 l of each HPLC fraction derived
from the in vitro digestion of CLG  5 peptide. CTLs incubated with
medium alone were used as negative control, whereas CTL stimulated with
PHA (Wellcome Diagnostics, Dartford, U.K.) represented the positive con-
trol. Plates were incubated for 24 h and washed, and then a biotinylated
anti-IFN- mAb (1 g/ml; Pierce) was added to the wells. After 60 min,
the plates were washed again and HRP-conjugated streptavidin (Pierce)
was added at room temperature for 45 min. Individual IFN--producing
cells were detected using 3-amino-9-ethylcarbazole cromogen kit (Sigma-
Aldrich) and counted by ELISPOT reader (AELVIS, Hannover, Germany).
The number of specific IFN--secreting T cells, expressed as spot-forming
cells per 106 cells, was calculated by subtracting the negative control
values.
FIGURE 1. Expression of proteasomes in LCL expressing the HIV-1 tat
gene. A, Equal amounts of proteins from total cell lysates from MIN and
MON LCLs transduced with pBabeP (MIN-0 and MON-0, respectively) or
with pBabeP-Tat (MIN-Tat and MON-Tat, respectively) were fractionated
by SDS-PAGE, transferred onto nitrocellulose filters, and probed with
mAbs or polyclonal antisera specific for the 2 subunit, PA28, LMP2,
LMP7, and MECL1. B, The intensity of specific bands was measured by
densitometry. Data are expressed as percentage of increase in ODs of spe-
cific bands detected in Tat-expressing cells relative to control cells.
Mean  SEM of four independent experiments is shown. C, Equal
amounts of purified proteasomes (1 g) were fractionated by SDS-PAGE,
transferred onto nitrocellulose filters, and probed with mAbs or polyclonal
antisera 2 subunit, LMP2, LMP7, and MECL1. One representative ex-
periment of four performed is shown. D, The intensity of specific bands
was measured by densitometry. Data are expressed as percentage of in-
crease in ODs of specific bands detected in proteasomes purified from
Tat-expressing cells relative to proteasomes from control cells. Mean 
SEM of three independent experiments is shown.
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Results
Endogenously expressed Tat or exogenous native Tat protein
modulates proteasome composition and activity
To evaluate the level of proteasome expression in the presence of
endogenous Tat, LCL were permanently transduced with a Tat-
expressing vector (MIN-Tat and MON-Tat) or the vector alone
(MIN-0 and MON-0), and total cell lysates were examined by
Western blot analysis with Abs specific for the constitutive 2
subunit of proteasomes. As shown in Fig. 1, all cells expressed
similar amounts of proteasomes. Because LCLs constitutively ex-
press immunoproteasomes (25), we then evaluated the expression
of the IFN--inducible PA28 regulator and that of the catalytic 
subunits LMP2, LMP7, and MECL1. Both LCL-Tat lines showed
no difference in the level of expression of PA28 as compared
with control cells. In contrast, Tat-expressing cells showed a
marked down-regulation of LMP2 and up-regulation of LMP7 and
MECL1 subunits, respectively (Fig. 1, A and B).
We then evaluated the expression of the catalytic subunits in-
corporated in proteasomes purified from cell lysates. Proteasomes
purified from Tat-expressing cells presented a down-regulation of
LMP2 and up-regulation of LMP7 and MECL1 subunits as com-
pared with proteasomes purified from vector-transduced cells (Fig.
1, C and D), respectively. Down-regulation of LMP2 and up-reg-
ulation of MECL1 and LMP7 were also observed at transcriptional
level (data not shown).
Increase of LMP7 and MECL1 and decrease of LMP2 were
detected in proteasome purified from a Jurkat cell line stably trans-
fected with Tat (JSL3-Tat) as compared with control JSL3-0 cells
(Fig. 2).
These findings indicate that the endogenous expression of Tat
protein modifies the catalytic subunit composition of
immunoproteasomes.
Because the HIV Tat protein is efficiently taken up by cells
(2–6), we tested the effect of exogenous Tat protein on protea-
somes in MIN and MON LCLs cultured in the absence or presence
of increasing concentrations (0.01–1 g/ml) of the native Tat pro-
tein. After treatment, proteasomes purified from Tat-treated cells
showed a down-regulation of LMP2 and an up-regulation of LMP7
and MECL1, as compared with proteasomes purified from un-
treated cells (Fig. 3). These results demonstrate that both endog-
enously expressed Tat and exogenous native Tat protein modify
the subunit composition of immunoproteasomes.
To investigate whether the differences in subunit composition
correlated with differences in enzymatic activity, we analyzed the
cleavage specificity of equal amounts of proteasomes isolated from
MIN-Tat, MON-Tat cells, or control cells. Chymotryptic-like,
tryptic-like, and postacidic activities were all augmented in pro-
teasomes purified from cells expressing Tat, as compared with
control cells (Fig. 4). This is in agreement with the pattern of
expression of the three catalytic subunits in Tat-expressing cells,
because activation of LMP7 and MECL1 expression is associated
with increased chymotryptic and tryptic activities, whereas a re-
duction of LMP2 expression is associated with an increased post-
acidic activity, respectively (10, 26, 27).
Tat modifies the generation and recognition of CTL peptide
epitopes derived from EBV latent Ags
Because proteasomes play a key role in the generation of CTL
epitopes, we investigated the effect of Tat on the presentation of
dominant or subdominant CTL epitopes using as models LCLs
endogenously expressing Tat or treated with the Tat protein.
LCLs were chosen because they express all EBV latent Ags,
including EBNA1, 2, 3, 4, 5, and 6, and LMP1 and 2. These Ags,
except for the nuclear Ag 1, are all targets of CTL and contain a
large number of well-characterized CTL epitopes (28). Therefore,
we evaluated the killing of LCLs expressing the immunodominant
FIGURE 2. Expression of proteasomes in Jurkat cells expressing the
HIV-1 tat gene. A, Equal amounts of purified proteasomes (1 g) from
Jurkat cells transfected with the vector alone (JSL3-0) or with the tat gene
(JSL3-Tat) were fractionated by SDS-PAGE, transferred onto nitrocellu-
lose filters, and probed with mAbs or polyclonal antisera specific for 2
subunit, LMP2, LMP7, and MECL1. One representative experiment of
four performed is shown. B, The intensity of specific bands was measured
by densitometry. Data are expressed as percentage of increase in ODs of
specific bands detected in proteasomes purified from Tat-expressing cells
relative to proteasomes from control cells. Mean  SEM of three inde-
pendent experiments is shown.
FIGURE 3. Expression of proteasome subunits in cells treated with the
HIV-1 Tat protein. A, MIN and MON LCLs were treated for 24 h at 37°C
with 0.01, 0.1, or 1 g/ml native Tat protein. Equal amounts of protea-
somes (1 g) were fractionated by SDS-PAGE, transferred onto nitrocel-
lulose filters, and probed with mAbs or polyclonal antisera specific for the
2 subunit, LMP2, LMP7, and MECL1. One representative experiment of
three performed is shown. B, The intensity of specific bands was measured
by densitometry. Data are expressed as percentage of increase in ODs of
specific bands detected in Tat-treated cells relative to control cells. Mean
SEM of three independent experiments is shown.
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IVT and AVF HLA-A11-presented epitopes (21), and the sub-
dominant YLQ and CLG HLA-A2-presented epitopes, respec-
tively (22, 23). To this end, the HLA-2- and HLA-A11-positive
MIN LCL and the HLA-A2-positive MON LCL, transduced or not
with Tat, were used as targets in cytotoxic assays using CTL cul-
tures specific for IVT, AVF, CLG, and YLQ epitopes (Fig. 5). As
expected, IVT- and AVF-specific CTLs efficiently lysed A11-
matched LCL (21). In contrast, YLQ- and CLG-specific CTLs rec-
ognized the target cells less efficiently (22–24). This is due to the
poor expression of these two epitopes on the surface of EBV-
infected B cells (28). However, a decrease in IVT- and AVF-spe-
cific CTL killing and an increase in YLQ- and CLG-specific kill-
ing were observed in Tat-expressing cells as compared with
control cells. No killing of the HLA-A11-negative MON LCL,
either expressing Tat or the empty vector, was observed by using
IVT- and AVF-specific CTL cultures (Fig. 5).
In a second set of experiments, we evaluated the CTL killing of
MIN LCL untreated or treated with 0.1 g/ml Tat protein. As
expected from the results of the previous experiments, LCLs
treated with Tat were less sensitive to IVT- and AVF-specific CTL
killing, but were lysed more efficiently by YLQ- and CLG-specific
CTLs (Fig. 6).
These findings suggested that the effect of Tat on proteasome
composition and enzymatic activity results in changes in epitope
presentation, leading to increased CTL recognition of subdominant
epitopes.
Efficient in vitro generation of the subdominant CLG epitope by
proteasomes purified from Tat-expressing cells
To confirm whether proteasomes from Tat-expressing cells are
able to generate subdominant epitopes more efficiently, we ana-
lyzed the in vitro degradation of a CLG peptide precursor contain-
ing 5 aa at the C terminus (CLG  5), corresponding to the wild-
type sequence of the LMP2 Ag. Proteasomes were purified from
MIN-Tat or MIN-0, and the in vitro CLG precursor degradation
was evaluated by HPLC analysis. We observed that after 2 h, pro-
teasomes isolated from control cells degraded 20% of the CLG 
5 peptide precursor, while proteasomes purified from Tat-express-
ing cells degraded 80% of the CLG  5 peptide (Fig. 7A). This
level of degradation was only reached by proteasomes from con-
trol cells after 24 h (data not shown).
We then determined the presence of CLG peptides/precursors
by testing the HPLC-fractionated digestion products for their ca-
pacity to activate CLG-specific CTLs by IFN- ELISPOT assays.
Fractions purified from digests obtained after 30, 60, and 90 min of
incubation, respectively, did not activate CTL responses (data not
shown), suggesting that they did not contain any active peptide. In
contrast, fractions 4 and 8, which were obtained after 120 min of
degradation by proteasomes purified from MIN-Tat, stimulated
CLG-specific CTL responses (Fig. 7B). This indicated that such
fractions contained the CLG epitope or a longer antigenic epitope.
In contrast, only a weak CLG-specific CTL response was observed
with HPLC fraction 8, obtained after 120 min of degradation by
proteasomes isolated from MIN-0 control cells. No HPLC fraction
able to stimulate CLG-specific CTL responses after 24 h of in vitro
degradation by proteasomes purified from control cells was de-
tected (data not shown).
These results indicate that proteasomes purified from Tat-ex-
pressing cells exhibit different proteolytic activity, capable of ef-
ficiently generating subdominant peptide epitopes.
Discussion
We have shown in this study that the HIV-1 Tat protein, an early
product of HIV-infected cells, modifies the subunit composition
FIGURE 4. Enzymatic activity of proteasomes in LCL expressing the
HIV-1 tat gene. Proteasomes (2.5 g) purified from cell lysates of the
indicated cell lines were incubated for 30 min at 37°C with Suc-LLVY-
AMC, Boc-LRR-AMC, and Ac-YVAD-AMC to evaluate chymotryptic-
like, tryptic-like, and postacidic activities, respectively. Data are expressed
as arbitrary fluorescence units. Mean  SEM of three independent exper-
iments is shown.
FIGURE 5. CTL killing of cells expressing the HIV-1 tat gene. The
HLA-A2-, HLA-A11-positive MIN and the HLA-A2-positive, HLA-A11-
negative MON LCLs transduced with pBabeP (MIN-0 and MON-0, re-
spectively) or with pBabeP-Tat (MIN-Tat and MON-Tat, respectively)
were used as targets in cytotoxic assays of CTLs specific for the HLA-
A11-presented, EBNA4-derived IVT and AVF epitopes, the HLA-A2-pre-
sented LMP1-derived YLQ epitope, and the HLA-A2-presented LMP2-
derived CLG epitope, respectively. Results are expressed as percentage of
specific lysis. The mean  SEM of the results from three independent
experiments is shown.
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and activity of proteasomes. In particular, we demonstrated that
proteasomes in cells of B and T cell origin, expressing an endog-
enous Tat or treated with a biologically active Tat protein, present
an up-regulation of the LMP7 and MECL1 subunits and a down-
modulation of the LMP2 subunit. Changes in proteasome subunit
composition induced by Tat result in the increase of all three major
proteolytic activities of the proteasomes.
Selective down-regulation of LMP2 by viral gene products has
already been observed (29, 40). Of note, the LMP2 gene is under
the control of the STAT1-IFN regulatory factor-1 (IRF-1) complex
that, after binding with LMP2 promoter, induces transcription. It is
therefore of interest that the Tat protein associates with IRF-1 (30),
and it is tempting to speculate that this may result in IRF-1 se-
questration and down-regulation of LMP2 transcription and
expression.
Of note, Tat-dependent LMP2 down-regulation, both at protein
and RNA levels (data not shown), did not affect the incorporation
of MECL1 into proteasomes. LMP2 incorporation into immuno-
proteasomes is an early event during assembly, and it has been
shown that subsequent incorporation of MECL1 normally requires
LMP2 (31, 32). This is due to a cooperative assembly process (33)
mediated by not yet defined MECL1 and LMP2 propeptide-protein
interactions. We speculate that Tat may also play a role in the
assembly of proteasomal subunits by interacting with MECL1
propeptide, resulting in MECL1 incorporation without the need of
LMP2. Indeed, it has recently been shown that Tat interacts with
both  subunits and LMP7 and MECL1 subunits of the proteasome
(14). Tat has also been shown to inhibit the proteolytic activity of
20S proteasome by competing with PA28 regulator for binding to
20S (15, 16). In contrast with these data, no effect on the expres-
sion of PA28 in Tat-expressing cells nor on the activity of immu-
noproteasomes treated in vitro with Tat protein was detected (data
not shown). However, we used a monomeric fully active Tat de-
rived from the human T cell leukemia virus-IIIB isolate (BH10
clone, subtype B), which lacks Asp67, shown by Huang et al. (16)
to be required for the interaction with the 20S core particle.
We also showed that changes of the proteolytic activities of
proteasomes in Tat-expressing LCLs or in LCLs treated with the
Tat protein correlate with a different presentation of EBV-derived
epitopes. In particular, Tat decreases the presentation of two im-
munodominant CTL epitopes (IVT and AVF) presented by HLA-
A11 molecules, and increases the presentation of two subdominant
epitopes (YLQ and CLG) presented by HLA-A2. In fact, protea-
somes from Tat-expressing cells are more efficient both in the deg-
radation of a CLG peptide precursor and in the generation of im-
munogenic CLG peptide fragments. A similar phenomenon has
been observed for an HLA-A2-presented epitope expressed in mel-
anoma cells (34), suggesting that the presence of LMP2 may spe-
cifically affect the range of peptides presented by some HLA class
I alleles (i.e., HLA-A2). Further confirming the critical role of the
LMP2 subunit in the generation of CTL epitopes, it has been dem-
onstrated that influenza-specific CTL responses to the two most
dominant determinants decrease in LMP2 knockout mice, whereas
responses to two subdominant epitopes are greatly enhanced (35).
Changes in immunodominance may be particularly relevant in
vaccination strategies aimed at the control of viral infections and
tumors. In fact, a decrease in the presentation of immunodominant
epitopes concomitant with an increase of subdominant and cryptic
epitopes may be beneficial for the elimination of virally infected or
tumor cells. Indeed, it is well established that immunodominant
epitopes are very prone to mutations and to CTL escape (36, 37),
while subdominant epitopes are more conserved and may induce
protective immune responses (38, 39).
In conclusion, our results demonstrate that the HIV-1 Tat pro-
tein modulates proteasome composition and activity, and that this
affects the generation of peptide Ags recognized by CTLs. These
FIGURE 6. CTL killing of cells treated with exogenous HIV-1 Tat pro-
tein. The HLA-A2-, HLA-A11-positive MIN LCLs, untreated or treated
with 0.1 g/ml Tat for 24 h, were used as target in cytotoxic assays of
CTLs specific for the HLA-A11-presented EBNA4-derived IVT and AVF
epitopes, the HLA-A2-presented LMP1-derived YLQ epitope, and the
HLA-A2-presented LMP2-derived CLG epitope, respectively. Results are
expressed as percentage of specific lysis. Results from one representative
experiment of three performed are shown.
FIGURE 7. In vitro degradation of a CLG epitope precursor by protea-
somes purified from Tat-expressing cells. A, The CLG  5 peptide was
incubated with proteasomes purified from MIN-Tat or from MIN-0 LCLs.
The precursor degradation was followed at different time points, and the
degradation of CLG  5 was evaluated by HPLC analysis. Data are ex-
pressed as percentage of degradation. The mean of the results from three
independent experiments is shown. B, The digestion products obtained af-
ter 120 min of degradation were purified by HLPC; the indicated fractions
were collected and tested by IFN- ELISPOT for their capacity to activate
CLG-specific CTLs. Data are expressed as spot-forming cells (SFC) per
106 cells. The mean of the results from three independent experiments,
performed in triplicates, is shown.
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data may have important implication in the immune recognition of
HIV-infected cells, the CTL control of HIV-associated viral infec-
tions and malignancies, and the immunogenicity of Tat itself. We
have shown recently that vaccination with Tat protein or tat DNA
protected monkeys against challenge with pathogenic simian HIV,
and that protection correlated with Th1 responses and CTL activity
(7, 8). Furthermore, we have shown that the Tat protein induces
maturation of DC and increases both allogeneic and recall Ag pre-
sentation by DC (6). These observations, together with the findings
presented in this work, suggest that native Tat is not only an Ag,
but also a novel adjuvant capable of modifying CTL epitope hi-
erarchy and responses against heterologous Ags favoring the gen-
eration of subdominant CTL epitopes. Therefore, the Tat protein
may represent an important tool for broadening the spectrum of the
epitopes recognized by CTLs, and for increasing the chances to
prevent the appearance of CTL escape in vaccine strategies against
HIV, and more in general against intracellular pathogens and
tumors.
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